AAI/CML's choice to use the Freeslate system as they expand their research capabilities speaks to the value these systems offer drug development researchers.
SUNNYVALE, CA and WILMINGTON, NC (PRWEB) September 30, 2015
Freeslate, Inc., the leading provider of high throughput research solutions for biopharmaceutical development, today announced that AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) has acquired a CM Protégé Powder Dispense System to support its existing Freeslate Core Module system for solid state screening and characterization. As Contract Development and Manufacturing Organizations (CDMOs) continue to adopt automation, AAI/CML is leading the way by deploying reliable, modular Freeslate systems dedicated to solid state screening and characterization to greatly increase the quality and capacity of work within its Weert, Netherlands facility.
The CM Protégé Powder Dispense System will allow researchers to eliminate bottlenecks associated with the repetitive task of dispensing numerous powders. With the large capacity, flexibility in dose format, and wide dynamic range of compatible materials facilitated by the Freeslate dispensing technologies, the CM Protégé Powder Dispense System was a natural choice for AAI/CML.
“Freeslate’s CM Protégé Powder Dispense System allows us to provide high throughput solutions for our clients in need of solid state screening, as we are expanding and positioning our Weert, Netherlands facility as our Center of Excellence for Solid State Chemistry,” said Syed Husain, Chief Commercial Officer of AAI/CML. “This type of equipment is what allows us to provide quick turnaround on solid state screening for our clients, enabling us to pass the benefits of improved productivity and data quality on to customers.”
“We are very pleased that AAI/CML has selected the CM Protégé to augment its existing Freeslate workflows,” said John S. Senaldi, President and CEO of Freeslate. “They have realized the benefits of automating solid state screening and characterization with the adoption of our Core Module system. The company’s choice to use the Freeslate system as they expand their research capabilities speaks to the value these systems offer drug development researchers.”
Freeslate is a privately held company providing laboratory automation products that dramatically improve the productivity and innovation of drug development organizations. For more than a decade, Freeslate has been working with customers to automate complex chemical research processes. Our resulting product line includes solutions for protein and vaccine drug formulation development, small molecule solubility, and polymorph screening and process chemistry.
Freeslate products are designed to accelerate innovation by screening a broader experimental space, limiting simplifying assumptions and delivering non-intuitive results. The CM Protégé Powder Dispense System leverages Freeslate’s proven proprietary powder dispense technologies. The flexibility of the system allows it to support a wide array of applications ranging from pharmaceutical development to chemical development. The platform can operate either as a stand-alone solution, or it can be integrated with other systems, like the Freeslate Core Module 3 (CM3) or CM Protégé automation systems to create an entire automated workflow. An optional positive displacement pipette enables the precise and accurate dispensing of liquids with viscosities up to 5000 cP.
We start with a scientific understanding of our customer’s bottlenecks and utilize our robust and proprietary automation platforms and integrated Lab Execution and Analysis (LEA) software suite to deliver solutions that make a difference. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit http://www.freeslate.com.
About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc.
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With seven sites across the globe, our combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. Contact us for all your drug development and manufacturing needs at http://www.aaipharma.com and http://www.c-mlabs.com.